10X Genomics

10X Genomics, Inc.Founded in 2012, 10X Genomics, Inc. is headquartered in Pleasanton, US. The company develops technology that streamlines genomic analysis.10X Genomics specializes in innovative genomic technology platforms that enhance biological research and advance human health. The company’s core products include the Chromium Single Cell platform, which allows researchers to perform transcriptomic profiling of up to a million single cells, revealing cellular diversity and characteristics on a granular level. Additionally, the Visium Spatial platform enables whole transcriptome analysis of fresh and fixed tissues while maintaining their morphological context, crucial for understanding disease mechanisms and cellular interactions. Their Xenium In Situ platform provides subcellular resolution mapping of RNA molecules within tissue sections. These advanced tools are primarily designed for research institutions, pharmaceutical companies, and biotech firms, which utilize them to unlock insights into gene expression, cellular behavior, and drug development across various therapeutic areas.56 mn.10X Genomics plans to launch new products designed to further enhance its genomic technology offerings. The company aims to expand into new markets including Europe and Asia by the end of 2024.00 mn will be utilized to support these initiatives, particularly in advancing product development and expanding market reach.

1. Series D

   Jan 7, 2019

   Amount

   $35M

   Investors

   Locked

2. Series D

   Apr 10, 2018

   Amount

   $50M

   Investors

   Locked

3. Series C

   Mar 17, 2016

   Amount

   $55M

   Investors

   Locked

4. Series B

   Dec 19, 2014

   Amount

   $56M

   Investors

   Locked

5. Series A

   Oct 8, 2012

   Amount

   $3M

   Investors

   Locked